An interventional study of Intellidrop Automated CSF Drainage System and Intellidrop Automated CSF Drainage System in NPH (Normal Pressure Hydrocephalus), sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 60 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Hydrocephalus, Normal Pressure with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Hydrocephalus, Normal Pressure · United States.
Among the 24 studies in Hydrocephalus, Normal Pressure with a site in United States, this one is the 13th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 24th registered.
78 studies on the registry are indexed under Hydrocephalus, Normal Pressure; 20 are open to participants now.
Browse Hydrocephalus, Normal Pressure studies →4 of the 24 studies in Hydrocephalus, Normal Pressure with a site in United States are open now. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 40+
University of South Florida · Sites in United States
Ages 40+
Johns Hopkins Bloomberg School of Public Health · Sites in United States
Ages 65+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Hydrocephalus, Normal Pressure studies recruiting now, 12 (75%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 60 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 49 across 40 interventional studies indexed under Hydrocephalus, Normal Pressure.
Median enrollment 30 across the 15 interventional studies, 20 across the 9 observational. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 24 have an industry lead sponsor. The 10 most frequent:
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
University of Texas Southwestern Medical Center has 1 study filed under Hydrocephalus, Normal Pressure — fewer than ten, so there is no comparison to draw.
4 of the studies in Hydrocephalus, Normal Pressure with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04011566University of South FloridaAssessment of ShuntCheck Performance Characteristics in Asymptomatic Patients With Normal Pressure Hydrocephalus | 2026-11 |
| NCT06498960CereVasc IncEvaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus | 2027-01 |
| NCT04309487University of South FloridaDiagnostic Accuracy of ShuntCheck Compared to Radionuclide Shunt: Patency in Patients With Normal Pressure Hydrocephalus | 2027-01 |
| NCT06426004Johns Hopkins Bloomberg School of Public HealthAddressing Health Disparities in Normal Pressure Hydrocephalus (NPH) in Maryland | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 24 studies in Hydrocephalus, Normal Pressure with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The intellidrop device is an FDA-approved system that automates safe, small volume of cerebral spinal fluid drainage with continuous pressure monitoring, reducing nursing workload and human error while improving patient mobility and comfort
The intellidrop (BrainSpace, Inc) was approved by the Food and Drug Administration (FDA) for use in automating CSF drainage while providing continuous intracranial pressure (ICP) monitoring. Control parameters can be programmed for requent removal of small volumes of fluid contingent on pressure remaining in target range, and with guardrails on volume drained over a range of timespans. This reduces the frequency and duration of nursing attention to managing the stopcock every four hours as in the current design and may reduce risk of human error. The compact and mobile design allows for more freedom for patient mobility, and importantly for patient satisfaction, there is no longer a need for the patient to lay supine for one out of every four hours because substantial (20mls) volumes of CSF are no longer removed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device
Device: Intellidrop Automated CSF Drainage System
Participants will undergo lumbar drainage using the Intellidrop automated cerebrospinal fluid drainage system that monitors intracranial or spinal pressure and manages external drainage of cerebrospinal fluid and other body fluids to a user selected pressure target or volume target. Its closed loop, gravity-based drainage ensures natural flow, while offering position-agnostic precision control to achieve an hourly target volume. It connects to the distal end of the lumbar catheter outside the body and replaces the drainage collection device and manual nursing effort.
Participants will undergo lumbar drainage using the Intellidrop automated cerebrospinal fluid drainage system that provides continuous intracranial pressure monitoring and automated control of CSF removal. It is programmed to withdraw small frequent volumes of CSF within predefined safety limits reducing the need for manual stopcock adjustments and minimizing human error. It is designed to improve workflow efficiency, enhance patient mobility, and evaluate the device;s feasibility, performance and safety during the lumbar drain.
Feasibility
The feasibility of the intervention will be measured using the feasibility of the intervention measure (FIM). The FIM is a four item instrument that evaluates feasibility. The four scores are sumed and divided by 5 to provide a final score ranging from 0 to 1.0 with higher score indicating greater feasibility.
Time frame: FIM scores will be obtained on a daily basis during month 3 - 5.
Acceptability
The acceptability of the intervention will be measured using the acceptablity of the intervention measure (AIM). The AIM is a four item instrument that evaluates feasibility. Similarly to the FIM score, the four scores are sumed and divided by 5 to provide a final score ranging from 0 to 1.0 with higher score indicating greater acceptablity.
Time frame: from enrollment to the end of three months or until 10 subjects have been enrolled
Plan to share: No
Started May 2026 (actual). Primary completion is estimated for Oct 2026, 5 months after the start.
Of 21 interventional studies with no phase under Hydrocephalus, Normal Pressure, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hydrocephalus, Normal Pressure →
University of Texas Southwestern Medical Center →